-
While we are generally a society focused on innovation from start-ups (and now all the incubators like Rock Health), there are a few big companies that are able to innovate while growing. That’s not always easy and companies often need some catalyst to make this happen. Right now, there are four...
Posted to
News
by
Enabling Healthy Decisions
on
Sun, Apr 28 2013
Filed under:
Filed under: Healthcare, incentives, HIT, Innovation, Technology, Pharma, ACO, exercise, PBM / Pharmacy, Managed Care, Books / Articles, Value Propositions, Marketing / Communications, Leadership, Consumerism, Press, mHealth, Walgreens, Care Management, PBMI, QuantifiedSelf, $WAG
-
Today, I’m giving my presentation at the PBMI conference in Las Vegas. This year, I choose to focus on the idea of shifting from fee-for-service to value-based contracting. People talk about this relative to ACOs (Accountable Care Organizations) and PCMHs (Patient Centered Medical Homes) from a...
Posted to
News
by
Enabling Healthy Decisions
on
Tue, Feb 19 2013
Filed under:
Filed under: Healthcare, adherence, Technology, Pharma, PPACA, PBM / Pharmacy, Books / Articles, Value Propositions, Marketing / Communications, mHealth, inVentiv Health, big data, Rx, PBM, Care Management, Reform, PBMI, Value-Based Contracting
-
12 Of 23 Companies As I mentioned a few weeks ago (2/2/13), I wanted to test and see if healthcare companies would respond to consumers via Twitter. To test this, I posted a fairly general question or message on Twitter to see the response (see below). Of the 23 companies that I sent a message [...]
Posted to
News
by
Enabling Healthy Decisions
on
Mon, Feb 11 2013
Filed under:
Filed under: Healthcare, Social Media, test, Twitter, Research, Technology, Pharma, Customer Service, PBM / Pharmacy, Managed Care, Marketing / Communications, Methodology, Consumerism, mHealth, pharmacy, PBM, Response Time
-
When you think of potatoes, where do you want them to come from? Idaho When you think of citrus, where do you want it to come from? Florida When you think of US wine, where do you want it to come from? Napa Valley When you think of generic drugs, where do you want them [...]
-
I must admit that I’ve heard very little about this decision from the Federal Appeals Court for the Second Circuit of Manhattan that decided that discussing off-label uses for prescription drugs was an issue of free speech. This could change the way pharmaceutical manufacturers interact with physicians...
Posted to
News
by
Enabling Healthy Decisions
on
Tue, Jan 8 2013
Filed under:
Filed under: Healthcare, Pharma, PBM / Pharmacy, Books / Articles, Marketing / Communications, Methodology, Consumerism, Words Matter, Rx, Care Management
-
If one takes a long view of the history of technological innovation in business, a pattern can be perceived: An innovation emerges A cohort of early adopters perceive its superiority to existing solutions, identify the benefits it can bring to their business, and begin to evangelise Resistance is encountered...
-
This acquisition has been in the news since I believe last August with board rejections and now it appears it has finally resolved and Genzyme will be purchased by Sanofi. This is a huge price tag at $20 Billion. You may or may not be familiar with Genzyme but back in 2009 they were in the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Feb 16 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Pharma, Biotech, Massachusetts, Mergers and Acquisitions, Sanofi-Aventis, Genzyme, research and development collaboration
-
Sales have fallen and I guess even that big reward from Boston Scientific for 2 billion in 2010 was not enough to keep things rolling along here. Apparently the stent business is growing in other places and sales are down to 2.5 billion from 4 billion just a few years ago. Other companies...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Thu, Feb 10 2011
Filed under:
Filed under: Medically Related, Technology, drugs, healthcare, Medical Devices, Pharma, Biotech, FDA, Stents, Recalls, Legal Suits, Investments, Boston Scientific, Johnson and Johson, Cordis
-
This is very cool if you have trademarks or are wanting to file one for sure. I can’t help but think in the pharma end of healthcare that Trademarkia will perhaps be used quite a bit. All the trademarks issued in the US since 1870 claim to be listed. I just went to the general page...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Feb 4 2011
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Social Networks, Pharma, Intelligence, Algorithms, websites, business, trademarks, Trademarkia, logos, US Patent and Trademark Office
-
Patrick Soon-Shiong M.D. is the Los Angeles billionaire investor who has scooped up the company. Overall the product is a good thing as far as the reminder system and keep folks on track. My only concerns is the privacy factors and the data that it creates for sale. In today’s world...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Feb 4 2011
Filed under:
Filed under: Medically Related, Technology, Insurance, Pharma/FDA News, EMR, drugs, healthcare, EHR, Pharma, PHR, Prescriptions, data bases, Business Intelligence, Fines, personal health record, Algorithms, formulas, Express Scripts, overcharges, Vitality, Cobert Report, nsurance
-
This is a game or situation that Johnson and Johnson seems to be good at with their multitude of legal cases with stents. This time they are on the losing end of the stick with a jury ruling they violated a patent. The same researcher also won a case against Boston Scientific on his design...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Sat, Jan 29 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Medical Devices, Pharma, Biotech, FDA, Stents, Recalls, Legal Suits, Investments, Boston Scientific, Johnson and Johson
-
It doesn’t get much more upfront than this with one mentioning their feelings on how the company is being run does it. The one quote below is interesting too in the fact that “everything is under control”? How come we have more recalls coming up all the time? As soon as one fire is...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Thu, Jan 27 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, healthcare, Investors, Pharma, FDA, Johnson and Johnson, Recalls, Wall Street, McNeil Consumer Healthcare, Bill Weldeon
-
Vilazodone is a modulator of serotonin neurotransmission to be used for treatment of Major Depression Disorders. Now there’s one more choice for depression, it’s amazing if you look how many of these are out there. BD From the website: “Nearly 2,900 patients have been exposed to vilazodone...
-
Employees according to this article will receive 90% of their bonuses, but that’s better than no bonuses and in years past many have received more than 100% of the amount they qualified for. One casualty of the consumer products good was the sale of St. Joseph’s aspirin this year. Johnson...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Jan 18 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Medical Devices, Pharma, Bonuses, Johnson and Johnson, Recalls, employees, reputation
-
This is interesting on how healthcare technologies are following us everywhere, even to CES, as much of the new technology is consumer medical devices. Part of the convention included a Digital Health Summit meeting and the press release originated from that area. Walgreens had enabled quite...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Sat, Jan 8 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, drugs, healthcare, Medical Records, Pharma, Retail Clinics, Pay for Performance, Data, Walgreens, pharmacists, CES, United, CMO